Overview
Sepsis-associated encephalopathy (SAE) refers to brain dysfunction occurring in patients with sepsis, often manifesting as cognitive impairment and increasing mortality risk 1.Diagnosis
Serum neuron specific enolase (NSE) levels may serve as a biomarker for diagnosing SAE 1.
Diagnostic accuracy of serum NSE for SAE requires further validation through systematic reviews and meta-analyses 1.Management
No specific drug classes or doses for SAE management are detailed in the provided abstracts 1.
Focus on managing underlying sepsis with appropriate antibiotics, fluid resuscitation, and source control 1.Special Populations
No specific guidance on pregnancy, pediatrics, elderly, or comorbidities related to SAE management is provided in the abstracts 1.Key Recommendations
Evaluate serum neuron specific enolase (NSE) levels as a potential biomarker for diagnosing sepsis-associated encephalopathy 1 (Evidence: Moderate).
Prioritize comprehensive sepsis management including targeted antibiotic therapy, hemodynamic stabilization, and addressing the source of infection 1 (Evidence: Expert opinion).
Further research is needed to establish robust diagnostic criteria and treatment protocols specifically for SAE across different patient populations 1 (Evidence: Expert opinion).References
1 Hu J, Xie S, Xia W, Huang F, Xu B, Zuo Z et al.. Meta-analysis of evaluating neuron specific enolase as a serum biomarker for sepsis-associated encephalopathy. International immunopharmacology 2024. link